International Stem Cell Corp. (ISCO) Brings the Many Advantages of hpSCs to the World Stage
International Stem Cell Corporation’s stem cell technology platform has been called one of the most important in modern medicine. The company owns the key patents for parthenogenetic stem cells (hpSCs), pluripotent stem cells derived from unfertilized oocytes (eggs) collected during in vitro fertilization. Since hpSCs are not derived from human embryos, the ethical issues that plague the use of embryonic stem cells are not an issue. It’s a derivation method that also provides unique advantages when it comes to the problem of cell rejection by the patient, since hpSCs have only the mother’s DNA. Such a limited DNA set means…